On the public citation graph

First-Line Tislelizumab Combined with Bevacizumab and CAPOX for Locally Advanced or Metastatic Gastroesophageal Adenocarcinomas with PD-L1 CPS <5: A Phase II Single-Arm Study

https://doi.org/10.2139/ssrn.5235089
0 signed · 36 inferred · view as graph

Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.

Is this your work? Sign in with ORCID and put your name on the claims that are yours.
Claim with ORCID
Reference health. See whether every reference in this work resolves to a known work and none has been retracted — and get a dated CiteStamped badge you can embed.
See reference health

What this work says

Outgoing claims: the papers this work cites, builds on, or argues with.

inferredcites →https://doi.org/10.1001/jamaoncol.2020.3370openalex-snapshot
Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer
inferredcites →https://doi.org/10.1007/s00262-018-2160-xopenalex-snapshot
The binding of an anti-PD-1 antibody to FcγRΙ has a profound impact on its biological functions
inferredcites →https://doi.org/10.1007/s10120-018-00909-5openalex-snapshot
Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 study
inferredcites →https://doi.org/10.1007/s12032-024-02434-1openalex-snapshot
The role of IL-17 in the pathogenesis and treatment of glioblastoma—an update on the state of the art and future perspectives
inferredcites →https://doi.org/10.1007/s40265-018-0903-9openalex-snapshot
Apatinib: A Review in Advanced Gastric Cancer and Other Advanced Cancers
inferredcites →https://doi.org/10.1016/j.annonc.2022.07.1341openalex-snapshot
1223P First-line lenvatinib (Len) + pembrolizumab (Pembro) + chemotherapy (Chemo) vs chemo in advanced/metastatic gastroesophageal adenocarcinoma: LEAP-015 safety run-in
inferredcites →https://doi.org/10.1016/j.annonc.2022.07.1345openalex-snapshot
1227P Regorafenib (REGO) with nivolumab (NIVO) and FOLFOX in HER2 negative esophagogastric cancer (EGC)
inferredcites →https://doi.org/10.1016/j.annonc.2022.07.1368openalex-snapshot
1250P Camrelizumab plus apatinib combined with POF in patients with untreated advanced gastric cancer (UAGC): A single-center, open-label, single-arm, phase II trial (SYLT-017)
inferredcites →https://doi.org/10.1016/j.annonc.2023.10.081openalex-snapshot
LBA80 Tislelizumab (TIS) plus chemotherapy (Chemo) vs placebo (PBO) plus chemo as first-line (1L) treatment of advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC): Final analysis results of the RATIONALE-305 study
inferredcites →https://doi.org/10.1016/j.biopha.2018.03.061openalex-snapshot
The role of bevacizumab on tumour angiogenesis and in the management of gynaecological cancers: A review
inferredcites →https://doi.org/10.1016/j.biopha.2019.109746openalex-snapshot
Synergic effect of PD-1 blockade and endostar on the PI3K/AKT/mTOR-mediated autophagy and angiogenesis in Lewis lung carcinoma mouse model
inferredcites →https://doi.org/10.1016/j.ccell.2015.08.004openalex-snapshot
FcγRs Modulate the Anti-tumor Activity of Antibodies Targeting the PD-1/PD-L1 Axis
inferredcites →https://doi.org/10.1016/j.ccell.2016.12.009openalex-snapshot
Normalization of Tumor Vessels by Tie2 Activation and Ang2 Inhibition Enhances Drug Delivery and Produces a Favorable Tumor Microenvironment
inferredcites →https://doi.org/10.1016/j.critrevonc.2023.104070openalex-snapshot
Combined immunotherapy for hepatocellular carcinoma: How to maximize immune checkpoint blockade synergic anti-tumor effect
inferredcites →https://doi.org/10.1016/j.ctrv.2020.102017openalex-snapshot
Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook
inferredcites →https://doi.org/10.1016/s0140-6736(13)61719-5openalex-snapshot
Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial
inferredcites →https://doi.org/10.1016/s0140-6736(21)00797-2openalex-snapshot
First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial
inferredcites →https://doi.org/10.1016/s0140-6736(21)01234-4openalex-snapshot
Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study
inferredcites →https://doi.org/10.1016/s1470-2045(14)70420-6openalex-snapshot
Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial
inferredcites →https://doi.org/10.1016/s1470-2045(23)00358-3openalex-snapshot
First-line regorafenib with nivolumab and chemotherapy in advanced oesophageal, gastric, or gastro-oesophageal junction cancer in the USA: a single-arm, single-centre, phase 2 trial
inferredcites →https://doi.org/10.1016/s1470-2045(23)00515-6openalex-snapshot
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial
inferredcites →https://doi.org/10.1038/s12276-020-00500-yopenalex-snapshot
Combination of anti-angiogenic therapy and immune checkpoint blockade normalizes vascular-immune crosstalk to potentiate cancer immunity
inferredcites →https://doi.org/10.1038/s41392-024-01773-9openalex-snapshot
First-line camrelizumab (a PD-1 inhibitor) plus apatinib (an VEGFR-2 inhibitor) and chemotherapy for advanced gastric cancer (SPACE): a phase 1 study
inferredcites →https://doi.org/10.1038/s41591-024-03450-4openalex-snapshot
First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trial
inferredcites →https://doi.org/10.1093/annonc/mdn713openalex-snapshot
Management of hypertension in angiogenesis inhibitor-treated patients
inferredcites →https://doi.org/10.1093/annonc/mdy540openalex-snapshot
Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: interim results of a randomized, phase II trial (ATTRACTION-4)
inferredcites →https://doi.org/10.1126/science.1104819openalex-snapshot
Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy
inferredcites →https://doi.org/10.1126/science.adf6493openalex-snapshot
Deterministic reprogramming of neutrophils within tumors
inferredcites →https://doi.org/10.1158/1078-0432.ccr-19-3561openalex-snapshot
Tislelizumab Plus Chemotherapy as First-line Treatment for Advanced Esophageal Squamous Cell Carcinoma and Gastric/Gastroesophageal Junction Adenocarcinoma
inferredcites →https://doi.org/10.1158/1078-0432.ccr-21-2241openalex-snapshot
Anlotinib Induces a T Cell–Inflamed Tumor Microenvironment by Facilitating Vessel Normalization and Enhances the Efficacy of PD-1 Checkpoint Blockade in Neuroblastoma
inferredcites →https://doi.org/10.1159/000088483openalex-snapshot
Investigating the Potential of Bevacizumab in Other Indications: Metastatic Renal Cell, Non-Small Cell Lung, Pancreatic and Breast Cancer
inferredcites →https://doi.org/10.1186/s13045-019-0737-2openalex-snapshot
Progress and challenges in HER2-positive gastroesophageal adenocarcinoma
inferredcites →https://doi.org/10.1517/17425255.2012.656845openalex-snapshot
Is the toxicity of anti-angiogenic drugs predictive of outcome? A review of hypertension and proteinuria as biomarkers of response to anti-angiogenic therapy
inferredcites →https://doi.org/10.3322/caac.21492openalex-snapshot
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
inferredcites →https://doi.org/10.3389/fonc.2021.749083openalex-snapshot
Efficacy and Response Biomarkers of Apatinib in the Treatment of Malignancies in China: A Review
inferredcites →https://doi.org/10.3390/cancers15164099openalex-snapshot
Role of Checkpoint Inhibitors in the Management of Gastroesophageal Cancers
Editorial review for independent work. ICSAC — the Institute for Complexity Science and Advanced Computing — runs a structured editorial panel for researchers publishing outside journals, and publishes on CiteStamp rails. Submission is free and goes through ORCID: icsacinstitute.org/submit.